

Friedemann Paul

Charité - Universitätsmedizin Berlin
Department of Neurology
Charitéplatz 1 | D-10117 Berlin
Phone: +49 (0)30 450-639705
Email: friedemann.paul@charite.de



Curriculum vitae

since 2016	Professor (W2), tenure professorship for Clinical and Experimental Neuroimmunology, Charité
2011 - 2016	Professor (W2), Neurology, NeuroCure Clinical Research Center, Charité
since 2010	Head, research group, Clinical and Experimental Neuroimmunology, Experimental and Clinical Research Center, Charité Campus Buch
since 2008	Head, research group, Clinical Neuroimmunology, NeuroCure Clinical Research Center, Charité
2004 - 2010	Resident and senior physician, Cecilie Vogt Clinic for Neurology, Charité since 2003
2002 - 2003	Resident in Neurology
2002 - 2003	Training in Psychiatry, Schlosspark Klinik Berlin
2001 - 2004	Training in Epileptology and Electroencephalography, Epilepsiezentrum Berlin-Brandenburg
1996 - 2001	Training in Neurology und Clinical Neurophysiology, Auguste Viktoria Klinikum, Berlin
1988 - 1995	Medical studies at Freie Universität Berlin; Clinical training in France, Israel, and Zimbabwe

Research fields

- Neuromyelitis optica (Devic's Syndrome)
- Neurodegeneration and Neuroprotection in Multiple Sclerosis (MS) and Experimental Autoimmune Encephalomyelitis (EAE)
- Neurological Complications of Chronic Inflammatory Bowel Diseases Diagnostic Tools in Neuroimmunology (Imaging (OCT, MRI, Ultrasound), Laboratory, and CSF Biomarkers)
- Association of structural damage and dysfunction of the visual system in autoimmune disorders of the Central Nervous System

Activities in the scientific community, honors, awards

since 2016	Medical Consultant for EU- Announcements for Research Programmes on Rare Diseases (E-RARE)
since 2015	Associate Editor "Neurology: Neuroimmunology and Neuroinflammation"
since 2014	Medical Consultant for Science Council (BfarM)
since 2013	Board member of the Competence Network Multiple Sclerosis (KKNMS)
since 2011	Member of the Guthy Jackson Foundation Clinical Consortium (www.guthyjacksonfoundation.org)
since 2011	Academic Editor, PLoS ONE

since 2009 Member, Editorial Board, EPMA Journal
since 2009 National representative, European Association for Predictive, Preventive and Personalised Medicine (EPMA)
since 2008 MS-Subkommittee der European Neurological Society (ENS)
since 2008 Co-initiator, NEMOS-Initiative, coordinator of the German Neuromyelitis optical study group (www.nemos-net.de)

Selected publications

Zimmermann H, Freing A, Kaufhold F, Gaede G, Bohn E, Bock M, Oberwahrenbrock T, Young KL, Dorr J, Wuerfel JT, Schippling S, Paul F, Brandt AU. Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. *Multiple sclerosis*. 2013;19(4):443-50.

Sinnecker T, Bozin I, Dorr J, Pfueller CF, Harms L, Niendorf T, Brandt AU, Paul F, Wuerfel J. Periventricular venous density in multiple sclerosis is inversely associated with T2 lesion count: a 7 Tesla MRI study. *Multiple sclerosis*. 2013;19(3):316-25.

Dinkin M, Paul F. Higher macular volume in patients with MS receiving fingolimod: positive outcome or side effect? *Neurology*. 2013;80(2):128-9.

Wuerfel J, Sinnecker T, Ringelstein EB, Jarius S, Schwindt W, Niendorf T, Paul F, Kleffner I, Dorr J. Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis. *Multiple sclerosis*. 2012;18(11):1592-9.

Sinnecker T, Mittelstaedt P, Dorr J, Pfueller CF, Harms L, Niendorf T, Paul F, Wuerfel J. Multiple sclerosis lesions and irreversible brain tissue damage: a comparative ultrahigh-field strength magnetic resonance imaging study. *Archives of neurology*. 2012;69(6):739-45.

Sinnecker T, Dorr J, Pfueller CF, Harms L, Ruprecht K, Jarius S, Bruck W, Niendorf T, Wuerfel J, Paul F. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. *Neurology*. 2012;79(7):708-14.

Kleiter I, Hellwig K, Berthele A, Kumpfel T, Linker RA, Hartung HP, Paul F, Aktas O, Neuromyelitis Optica Study G. Failure of natalizumab to prevent relapses in neuromyelitis optica. *Archives of neurology*. 2012;69(2):239-45.

Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss JH, Neuhaus O, Etrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pellkofer H, Ziemann U, Kern P, Wandinger KP, Bergh FT, Boettcher T, Langel S, Liebetrau M, Rommer PS, Niehaus S, Munch C, Winkelmann A, Zettl UU, Metz I, Veauthier C, Sieb JP, Wilke C, Hartung HP, Aktas O, Paul F. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. *J Neuroinflammation*. 2012;9:14.

Brandt AU, Oberwahrenbrock T, Ringelstein M, Young KL, Tiede M, Hartung HP, Martin R, Aktas O, Paul F, Schippling S. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. *Brain*. 2011;134(Pt 11):e193; author reply e4.

Bellmann-Strobl J, Wuerfel J, Aktas O, Dorr J, Wernecke KD, Zipp F, Paul F. Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis. *Neurology*. 2009;73(20):1624-7.